| Literature DB >> 25246622 |
Willemijn J Van Rijt1, M Rebecca Heiner-Fokkema2, Gideon J du Marchie Sarvaas3, Hans R Waterham4, Robert G T Blokpoel5, Francjan J van Spronsen1, Terry G J Derks6.
Abstract
Multiple acyl coenzyme A dehydrogenase deficiency (MADD) is a severe inborn error of metabolism. Experiences with sodium-D,L-3-hydroxybutyrate (3-HB) treatment are limited although positive; however, the general view on outcome of severely affected patients with MADD is relatively pessimistic. Here we present an infant with MADD in whom the previously reported dose of 3-HB did not prevent the acute, severe, metabolic decompensation or progressive cardiomyopathy in the subsequent months. Only after a physiologic dose of 2600 mg/kg of 3-HB per day were ketone bodies detected in blood associated with improvement of the clinical course, N-terminal prohormone of brain natriuretic peptide and echocardiographic parameters. Long-term studies are warranted on 3-HB treatment in patients with MADD.Entities:
Keywords: cardiomyopathy; mitochondrial fatty acid oxidation; multiple acyl coenzyme A dehydrogenase deficiency; sodium-d,l-3-hydroxybutyrate
Mesh:
Substances:
Year: 2014 PMID: 25246622 DOI: 10.1542/peds.2013-4254
Source DB: PubMed Journal: Pediatrics ISSN: 0031-4005 Impact factor: 7.124